Literature DB >> 6429141

Activation of phospholipase C is dissociated from arachidonate metabolism during platelet shape change induced by thrombin or platelet-activating factor. Epinephrine does not induce phospholipase C activation or platelet shape change.

W Siess, P C Weber, E G Lapetina.   

Abstract

The present study compares the molecular mechanism by which thrombin, platelet-activating factor, and epinephrine induce platelet activation. Thrombin and platelet-activating factor induce an initial activation of phospholipase C, as measured by formation of 1,2-diacylglycerol and phosphatidic acid, during platelet shape change which is independent of and dissociated from metabolism of arachidonic acid. Phospholipase C activation and shape change are independent of extracellular Ca2+ and Mg2+. Formation of cyclooxygenase products occurs subsequent to the initial activation of phospholipase C and those metabolites are associated with platelet aggregation and further activation of phospholipase C. On the other hand, epinephrine is an unique platelet stimulus since it requires extracellular divalent cations and does not induce platelet shape change or activation of phospholipase C. Our results indicate that activation of phospholipase C may be a mechanism by which physiological agonists can activate platelets independently of extracellular divalent cations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6429141

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Integrin αIIbβ3: a novel effector of Gα13.

Authors:  Ramya Chari-Turaga; Ulhas P Naik
Journal:  Cell Adh Migr       Date:  2011-01-01       Impact factor: 3.405

2.  Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glycoprotein IIB-IIIA complex of human platelets.

Authors:  G van Willigen; J W Akkerman
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

3.  Increased endothelial albumin permeability mediated by protein kinase C activation.

Authors:  J J Lynch; T J Ferro; F A Blumenstock; A M Brockenauer; A B Malik
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

4.  Ionophore A23187 induces a refractory state in thrombin-activated release of inositol phosphates.

Authors:  G Moscat; F Moreno; S Iglesias; P Garcia-Barreno; A M Municio
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

5.  Inositol 1,4,5-triphosphate-induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin.

Authors:  L F Brass; C C Shaller; E J Belmonte
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

6.  Selective inhibition of adrenaline-induced human platelet aggregation by the structurally related Paf antagonist Ro 19-3704.

Authors:  M Schattner; A Parini; F Fouque; B B Vargaftig; L Touqui
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

7.  1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.

Authors:  G Grigoriadis; A G Stewart
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

8.  Effects of activation of protein kinase C on the agonist-induced stimulation and inhibition of cyclic AMP formation in intact human platelets.

Authors:  K A Williams; W Murphy; R J Haslam
Journal:  Biochem J       Date:  1987-05-01       Impact factor: 3.857

9.  myo-Inositol 1,4,5-trisphosphate stimulates protein phosphorylation in saponin-permeabilized human platelets.

Authors:  E G Lapetina; S P Watson; P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

Review 10.  Harnessing the platelet signaling network to produce an optimal hemostatic response.

Authors:  Lawrence F Brass; Maurizio Tomaiuolo; Timothy J Stalker
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-11       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.